The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Videos  >  

Results of a Phase II Study of Palbociclib in Esophageal and Gastric Cancer

Thomas Karasic, MD
Published Online:2:46 PM, Mon February 19, 2018


Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced 
esophageal or gastric cancer.

The efficacy was not particularly notable among the 21 patients on this study, Karasic notes. Five of the patients achieved stable disease for greater than 2 months and 2 of the patients achieved stable disease for greater than 4 months. The patient with the longest duration of response was the only patient who continued trastuzumab (Herceptin) on study. 

A single agent, palbociclib did not demonstrate efficacy to warrant moving forward to a larger trial, but perhaps targeting a growth pathway in addition using palbociclib might be effective, Karasic says.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.